Phio Pharmaceuticals Initiates Toxicology Study for PH-762, Aiming for 2026 Market Launch
- Critical Research Initiation: Phio Pharmaceuticals has commenced a toxicology study for PH-762, a crucial step mandated by the FDA that aims to pave the way for human pivotal trials, thereby accelerating the drug development process and enhancing market competitiveness.
- Clear Commercialization Goals: The company plans to launch a commercially viable product that meets FDA current Good Manufacturing Practices by 2026, a target supported by recent financing, demonstrating Phio's proactive response to market demands.
- Clinical Trial Progress: In the ongoing Phase 1b trial, 6 out of 18 skin cancer patients achieved 100% tumor clearance, indicating PH-762's potential as a non-surgical treatment option for skin cancers, which could significantly impact treatment paradigms.
- Strengthened Strategic Partnerships: Phio has entered into a comprehensive drug substance development services agreement with a U.S. manufacturing company, ensuring that clinical supplies for PH-762 meet cGMP standards, which will enhance production capabilities and expedite the product's market entry.
Trade with 70% Backtested Accuracy
Analyst Views on PHIO
About PHIO
About the author
Phio Pharmaceuticals Initiates Toxicology Study for PH-762, Aiming for 2026 Market Launch
- Critical Research Initiation: Phio Pharmaceuticals has commenced a toxicology study for PH-762, a crucial step mandated by the FDA that aims to pave the way for human pivotal trials, thereby accelerating the drug development process and enhancing market competitiveness.
- Clear Commercialization Goals: The company plans to launch a commercially viable product that meets FDA current Good Manufacturing Practices by 2026, a target supported by recent financing, demonstrating Phio's proactive response to market demands.
- Clinical Trial Progress: In the ongoing Phase 1b trial, 6 out of 18 skin cancer patients achieved 100% tumor clearance, indicating PH-762's potential as a non-surgical treatment option for skin cancers, which could significantly impact treatment paradigms.
- Strengthened Strategic Partnerships: Phio has entered into a comprehensive drug substance development services agreement with a U.S. manufacturing company, ensuring that clinical supplies for PH-762 meet cGMP standards, which will enhance production capabilities and expedite the product's market entry.
Three Penny Stocks to Keep an Eye on as of November 4, 2025
Penny Stocks to Watch: Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are highlighted as top penny stocks to monitor on November 4, 2025, based on their high Dollar Volume and market activity.
Generation Essentials Group: This France-based media company saw a Dollar Volume of $308 million and a 123% stock price increase after announcing a share repurchase program and plans to acquire hotels globally.
Phio Pharmaceuticals: The biotech firm experienced a Dollar Volume of $301.44 million despite a 9.3% decline in stock price, following positive trial results for its cancer treatment, which initially surged by nearly 75%.
Caribou Biosciences: With a Dollar Volume of $166.10 million, Caribou's stock reached a 52-week high after positive analyst ratings and promising data on its CRISPR gene-editing therapies for difficult-to-treat cancers.
What’s Driving the Surge in Phio Pharmaceuticals Stock Today?
Phio Pharmaceuticals Update: Shares of Phio Pharmaceuticals Corp. rose significantly after announcing positive results from its ongoing Phase 1b trial for treating cutaneous squamous cell carcinoma (cSCC), with one patient achieving 100% tumor clearance.
Trial Results: Out of 18 patients treated, six showed complete responses, while others demonstrated varying degrees of tumor clearance, and no patients experienced clinical progression of the disease.
Stock Performance: The stock surged over 30% on Monday, trading at $2.73, and is currently above its 50-day and 200-day moving averages, indicating a strong upward trend.
Market Sentiment: The bullish sentiment surrounding Phio Pharmaceuticals may attract further investor interest, although the stock faces potential resistance near its 52-week high of $9.78.
Monday's Major Stock Market Highlights: Morning News Summary!
Market Overview: Traders are encouraged to explore significant stock market stories as the week begins, highlighting key happenings to watch for on Monday.
Source for More Information: Additional top stock market stories can be found at TipRanks, providing further insights for traders.
Phio Pharmaceuticals Shares Drop 5% Following Financing and Clinical News
Stock Performance: Phio Pharmaceuticals Corp. (PHIO) shares fell 5.61% to $1.9350 after announcing the exercise of warrants to raise approximately $2.5 million and reporting positive results from its cancer therapy trial.
Warrant Exercise Details: The company exercised 928,596 warrants at prices of $2.00 and $2.485 per share, issuing new warrants for up to 1,857,192 additional shares at $2.485.
Clinical Trial Results: In a Phase 1b study of its INTASYL® therapy for cutaneous squamous cell carcinoma, 100% tumor clearance was achieved in 2 out of 3 patients in the third cohort.
Market Activity: On the announcement day, PHIO's stock opened at $2.04, fluctuated between $1.92 and $2.06, and saw increased trading volume due to investor concerns over warrant dilution and early efficacy signals.
What’s Behind the 75% Surge in Phio Pharmaceuticals Stock Today?
Stock Rally: Phio Pharmaceuticals (PHIO) stock surged 76.59% in pre-market trading after announcing positive results from a Phase 1b trial of its INTASYL gene-silencing technology aimed at treating cancer.
Clinical Trial Results: The trial showed significant cancer elimination in three patients with cutaneous squamous cell carcinoma, with one patient achieving 100% elimination and others showing 90% and 50% reductions.
CEO Statement: Robert Bitterman, CEO of Phio Pharmaceuticals, highlighted the trial's outcomes as a promising step towards a non-surgical treatment alternative for cutaneous carcinomas.
Analyst Ratings: Wall Street analysts have a consensus rating of Moderate Buy for PHIO, with a price target of $14, indicating a potential upside of nearly 583% for the stock.
Phio Pharmaceuticals Initiates Toxicology Study for PH-762, Aiming for 2026 Market Launch
- Critical Research Initiation: Phio Pharmaceuticals has commenced a toxicology study for PH-762, a crucial step mandated by the FDA that aims to pave the way for human pivotal trials, thereby accelerating the drug development process and enhancing market competitiveness.
- Clear Commercialization Goals: The company plans to launch a commercially viable product that meets FDA current Good Manufacturing Practices by 2026, a target supported by recent financing, demonstrating Phio's proactive response to market demands.
- Clinical Trial Progress: In the ongoing Phase 1b trial, 6 out of 18 skin cancer patients achieved 100% tumor clearance, indicating PH-762's potential as a non-surgical treatment option for skin cancers, which could significantly impact treatment paradigms.
- Strengthened Strategic Partnerships: Phio has entered into a comprehensive drug substance development services agreement with a U.S. manufacturing company, ensuring that clinical supplies for PH-762 meet cGMP standards, which will enhance production capabilities and expedite the product's market entry.
Three Penny Stocks to Keep an Eye on as of November 4, 2025
Penny Stocks to Watch: Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are highlighted as top penny stocks to monitor on November 4, 2025, based on their high Dollar Volume and market activity.
Generation Essentials Group: This France-based media company saw a Dollar Volume of $308 million and a 123% stock price increase after announcing a share repurchase program and plans to acquire hotels globally.
Phio Pharmaceuticals: The biotech firm experienced a Dollar Volume of $301.44 million despite a 9.3% decline in stock price, following positive trial results for its cancer treatment, which initially surged by nearly 75%.
Caribou Biosciences: With a Dollar Volume of $166.10 million, Caribou's stock reached a 52-week high after positive analyst ratings and promising data on its CRISPR gene-editing therapies for difficult-to-treat cancers.
What’s Driving the Surge in Phio Pharmaceuticals Stock Today?
Phio Pharmaceuticals Update: Shares of Phio Pharmaceuticals Corp. rose significantly after announcing positive results from its ongoing Phase 1b trial for treating cutaneous squamous cell carcinoma (cSCC), with one patient achieving 100% tumor clearance.
Trial Results: Out of 18 patients treated, six showed complete responses, while others demonstrated varying degrees of tumor clearance, and no patients experienced clinical progression of the disease.
Stock Performance: The stock surged over 30% on Monday, trading at $2.73, and is currently above its 50-day and 200-day moving averages, indicating a strong upward trend.
Market Sentiment: The bullish sentiment surrounding Phio Pharmaceuticals may attract further investor interest, although the stock faces potential resistance near its 52-week high of $9.78.
Monday's Major Stock Market Highlights: Morning News Summary!
Market Overview: Traders are encouraged to explore significant stock market stories as the week begins, highlighting key happenings to watch for on Monday.
Source for More Information: Additional top stock market stories can be found at TipRanks, providing further insights for traders.
Phio Pharmaceuticals Shares Drop 5% Following Financing and Clinical News
Stock Performance: Phio Pharmaceuticals Corp. (PHIO) shares fell 5.61% to $1.9350 after announcing the exercise of warrants to raise approximately $2.5 million and reporting positive results from its cancer therapy trial.
Warrant Exercise Details: The company exercised 928,596 warrants at prices of $2.00 and $2.485 per share, issuing new warrants for up to 1,857,192 additional shares at $2.485.
Clinical Trial Results: In a Phase 1b study of its INTASYL® therapy for cutaneous squamous cell carcinoma, 100% tumor clearance was achieved in 2 out of 3 patients in the third cohort.
Market Activity: On the announcement day, PHIO's stock opened at $2.04, fluctuated between $1.92 and $2.06, and saw increased trading volume due to investor concerns over warrant dilution and early efficacy signals.
What’s Behind the 75% Surge in Phio Pharmaceuticals Stock Today?
Stock Rally: Phio Pharmaceuticals (PHIO) stock surged 76.59% in pre-market trading after announcing positive results from a Phase 1b trial of its INTASYL gene-silencing technology aimed at treating cancer.
Clinical Trial Results: The trial showed significant cancer elimination in three patients with cutaneous squamous cell carcinoma, with one patient achieving 100% elimination and others showing 90% and 50% reductions.
CEO Statement: Robert Bitterman, CEO of Phio Pharmaceuticals, highlighted the trial's outcomes as a promising step towards a non-surgical treatment alternative for cutaneous carcinomas.
Analyst Ratings: Wall Street analysts have a consensus rating of Moderate Buy for PHIO, with a price target of $14, indicating a potential upside of nearly 583% for the stock.
